AZD8835 + fulvestrant

AZD8835 + fulvestrant is an investigational combination therapy being studied for the treatment of advanced solid tumors, particularly in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer. AZD8835 is a small molecule inhibitor targeting components of the PI3 kinase pathway, which plays a key role in cancer cell growth and survival. Fulvestrant is an estrogen receptor antagonist that binds to and downregulates estrogen receptors on breast cancer cells, thereby blocking the proliferative action of estrogen. The combination aims to overcome resistance mechanisms and improve outcomes in patients whose disease has progressed on prior anti-estrogen therapies[1][3][6].